Coronado Biosciences (CNDO) 2.18 $CNDO
Coronado Biosciences, Inc. (CNDO) in Focus: Stock Soars 17.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 8:18AM CST
Coronado Biosciences, Inc. (CNDO) was a big mover last session, as the company saw its shares rise by nearly 18% on the day.
ANIP: 54.28 (+2.33), CNDO: 2.18 (-0.11), AMAG: 40.04 (-0.79), AFFX: 8.94 (-0.36)
Coronado Bio powers up in late trading
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 3:07PM CST
CNDO: 2.18 (-0.11)
Coronado Biosciences (CNDO) Jumps: Stock Rises 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 7:51AM CST
Coronado Biosciences, Inc. (CNDO) was a big mover last session, as its shares rose nearly 9% on the day.
BIIB: 344.49 (+2.16), CNDO: 2.18 (-0.11), ANIP: 54.28 (+2.33), AMAG: 40.04 (-0.79)
Warren Buffett Pick CBI Tumbles On Rating Downgrade
at The Street - Mon Nov 24, 12:00PM CST
Amicus Therapeutics, Inc. (NASDAQ:FOLD), Coronado Biosciences Inc (NASDAQ:CNDO) and Receptos Inc (NASDAQ:RCPT) hit midday posting major gains this Monday. Getting a sluggish start to the week are Fa...
CBI: 39.14 (-1.17), FATE: 3.69 (+0.01), CNDO: 2.18 (-0.11), RCPT: 120.08 (-1.38), FOLD: 8.15 (+0.18)
CB Pharma on deck for IPO
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 10:46AM CST
IPO: 22.83 (-0.07), BIS: 46.11 (+0.99), BIB: 128.83 (-3.16), CNDO: 2.18 (-0.11), IBB: 306.10 (-3.95), DRGS: 52.31 (-1.38), IXJ: 101.03 (-1.47), IRY: 47.43 (-0.71)
Rackspace Bounces, Making Dan Loeb $34 Million In The Process
at The Street - Tue Nov 11, 1:06PM CST
Coronado Biosciences Inc (NASDAQ:CNDO), Rackspace Hosting, Inc. (NYSE:RAX) and AuRico Gold Inc (NYSE:AUQ) are making notable climbs on the stock market this Tuesday. Town Sports International Holding...
RDUS: 26.38 (+1.78), CLUB: 6.22 (+0.01), RAX: 45.39 (-0.86), CNDO: 2.18 (-0.11), AUQ: 3.30 (-0.02)
InsiderInsights.com Daily Round Up 11/10/14: CHK, TWX, SGEN, PBFX
InsiderInsights - at Seeking Alpha - Tue Nov 11, 2:29AM CST
HAS: 56.06 (-0.24), VR: 40.85 (-0.48), SEIC: 39.56 (-0.69), DRNA: 12.88 (+1.19), HA: 23.65 (-0.26), SAM: 279.40 (-0.97), PBFX: 20.00 (-0.76), AMRI: 15.84 (-0.14), GSAT: 2.58 (+0.05), TNET: 30.06 (-0.19), TWX: 82.12 (-1.19), HLT: 25.87 (-0.39), Q: 57.37 (-0.11), SGEN: 32.25 (-1.49), CF: 248.80 (-3.12), OPK: 8.18 (-0.11), CHK: 17.24 (+0.53), CNDO: 2.18 (-0.11), CO: 4.25 (-0.09), CPLA: 69.55 (+1.23)
Coronado Biosciences Raises $3,500,000 Through the Private Placement of Restricted Common Stock
GlobeNewswire - Fri Nov 07, 7:38AM CST
Shares were sold at the closing price on November 6, 2014
CNDO: 2.18 (-0.11)
Coronado Biosciences Reports Financial Results
GlobeNewswire - Thu Nov 06, 6:08AM CST
Coronado Biosciences, Inc. (Nasdaq:CNDO) announced its financial results for the third quarter ended September 30, 2014. Coronado's net cash and restricted cash totaled $71.6 million and $15.4 million respectively at September 30, 2014. The Company posted a quarterly net loss of $4.6 million and $16.7 million, or $0.13 and $0.46 per share for the three and nine months ended September 30, 2014 respectively. These results compare to a net loss of $7.8 million and $27.4 million, or $0.24 and $0.95 per share for the three and nine months ended September 30, 2013 respectively.
CNDO: 2.18 (-0.11)
EC approves ulcerative colitis med
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 10:31AM CDT
SGYP: 2.93 (-0.05), JNJ: 104.43 (-2.29), ABT: 43.69 (-0.77), CNDO: 2.18 (-0.11), PFE: 30.95 (-0.70), SHPG: 213.70 (-0.41), VBLX: 11.15 (+0.15), SLXP: 103.36 (-2.79), RCPT: 120.08 (-1.38), ABBV: 65.27 (-1.76), ATHX: 1.36 (+0.05)
Coronado Biosciences Forms Subsidiary to Acquire and License Dermatology Products for Commercialization
GlobeNewswire - Wed Oct 08, 7:35AM CDT
Coronado Biosciences, Inc. (Nasdaq:CNDO) has formed a wholly owned subsidiary, Journey Medical Corporation (JMC), to acquire and license dermatology products. Under the leadership of Claude Maraoui, CEO, JMC will begin building a portfolio of dermatological assets focused on acne, steroid responsive dermatoses, pigmentation and antifungals for promotion to dermatologists and pediatricians.
CNDO: 2.18 (-0.11)
Kamada Plunges Following Missed Marks In Trial
at The Street - Thu Sep 04, 11:52AM CDT
UTi Worldwide Inc. (NASDAQ:UTIW), Flexion Therapeutics Inc (NASDAQ:FLXN) and PVH Corp (NYSE
VH) are today's top-gaining billionaire stock picks midday. On the losing end are Kamada Ltd (NASDAQ:KM...
UTIW: 11.07 (-0.33), FLXN: 18.91 (+1.60), CNDO: 2.18 (-0.11), KMDA: 3.51 (-0.02), CIEN: 18.12 (-0.02), PVH: 127.03 (+1.47)
Coronado Falls on TSO Study Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 10:20AM CDT
Coronado (CNDO) announced disappointing top-line results from a pilot study on TSO.
BIIB: 344.49 (+2.16), MDCO: 25.39 (-0.19), CNDO: 2.18 (-0.11), REGN: 416.44 (-7.91)
Coronado Biosciences Reports Topline Results From Investigator Initiated Pilot Study of TSO in Adults With Autism Spectrum Disorder
GlobeNewswire - Thu Jun 26, 7:50AM CDT
Coronado Biosciences, Inc. (Nasdaq:CNDO) today announced that Dr. Eric Hollander, Clinical Professor Psychiatry and Behavioral Sciences at Albert Einstein College of Medicine of Yeshiva University and Director of the Autism and Obsessive Compulsive Spectrum Program at Montefiore Medical Center and Einstein has completed his pilot study of oral TSO (Trichuris suis ova or CNDO-201) for adults with Autism Spectrum Disorder (ASD).
CNDO: 2.18 (-0.11)
Autism - Pipeline Review, H1 2014 - 20 Companies & 42 Drug Profiles
M2 - Fri Jun 20, 2:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ltzhjv/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Dainippon Sumitomo Pharma Co., Ltd. - Novartis AG - Merz Pharma GmbH & Co. KgaA - Teva Pharmaceutical Industries Limited - Avanir Pharmaceuticals, Inc. - Snowdon Inc. - Curemark, LLC - Coronado Biosciences, Inc. - Omeros Corporation - Intra-Cellular Therapies, Inc. - Cellceutix Corporation - Heptares Therapeutics Ltd. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Naurex, Inc. - Nectid, Inc. - Mnemosyne Pharmaceuticals, Inc. - BioCrea GmbH - Saniona AB Drug Profiles - CM-AT - lurasidone hydrochloride - aripiprazole - cycloserine - fluoxetine - oxytocin - oxytocin - memantine hydrochloride - TSO - pioglitazone hydrochloride - oxytocin - oxytocin - (dextromethorphan hydrobromide quinidine sulfate) - oxytocin - oxytocin - RG-7314 - fluoxetine - fluoxetine - argipressin tannate - NU-211-01 NC-215-01 - Autologous Hematopoietic Stem Cells - glatiramer acetate - ITI-007 - Stem Cell Therapy for Central Nervous System Disorders - KM-391 - Program For Neurological Disorders - STX-110 - CN-2097 - acamprosate calcium - Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome For more information visit http://www.researchandmarkets.com/research/lt...m_pipeline
CNDO: 2.18 (-0.11), TEVA: 55.92 (-0.92), ITCI: 15.79 (-0.47), OMER: 22.81 (+0.12), NVS: 93.52 (-0.82)
Global Autism Clinical Trials Review 2014
M2 - Tue Jun 17, 9:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vhfbw6/autism_global) has announced the addition of the "Autism Global Clinical Trials Review, H1, 2014" report to their offering. Autism Global Clinical Trials Review, H1, 2014 provides data on the Autism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Autism. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Autism. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Autism Speaks, Inc. - Seaside Therapeutics, LLC - Forest Laboratories, Inc. - Johnson & Johnson - Otsuka Holdings Co., Ltd. - F. Hoffmann-La Roche Ltd. - Bristol-Myers Squibb Company - Coronado Biosciences, Inc. - ZonMw - Dainippon Sumitomo Pharma Co., Ltd. - National Institute of Mental Health - Massachusetts General Hospital - Tehran University of Medical Sciences - Eunice Kennedy Shriver National Institute of Child Health and Human Development - Hugo W. Moser Research Institute at Kennedy Krieger, Inc. - Stanford University - The University of Hong Kong - University of California, Los Angeles - Mount Sinai Hospital - University of California, San Francisco For more information visit http://www.researchandmarkets.com/research/vh...ism_global
JNJ: 104.43 (-2.29), CNDO: 2.18 (-0.11), BMY: 58.75 (-0.93), FRX: 99.00 (-0.77)
Arkansas Leading Change in College Student Experience
Marketwire - Tue Feb 25, 6:04AM CST
Today, Achieving the Dream released Continuous Improvement for College Completion: Arkansas Builds a System-Level Strategy for Community College Student Success during a session at DREAM 2014. This report details the coordinated efforts of Arkansas that has significantly improved the progress of student outcomes at two-year colleges across the state.
CNDO: 2.18 (-0.11)
Healthcare Companies Report Interim Data, Clinical Study Results, and Announcements - Research Report on Pfizer, Coronado Biosciences, Spectranetics, Celsion, and Intercept
PR Newswire - Wed Dec 18, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Coronado Biosciences, Inc. (NASDAQ: CNDO), The Spectranetics Corporation (NASDAQ: SPNC), Celsion Corp. (NASDAQ: CLSN), and Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
SPNC: 34.37 (+0.70), CLSN: 2.42 (unch), CNDO: 2.18 (-0.11), AUQ: 3.30 (-0.02), PFE: 30.95 (-0.70), ICPT: 137.69 (-2.48), AUQ.TO: 3.82 (-0.01)
Coronado Biosciences, Inc. (CNDO) in Focus: Stock Soars 17.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 8:18AM CST
Coronado Biosciences, Inc. (CNDO) was a big mover last session, as the company saw its shares rise by nearly 18% on the day.
ANIP: 54.28 (+2.33), CNDO: 2.18 (-0.11), AMAG: 40.04 (-0.79), AFFX: 8.94 (-0.36)
Coronado Bio powers up in late trading
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 3:07PM CST
CNDO: 2.18 (-0.11)
Coronado Biosciences (CNDO) Jumps: Stock Rises 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 7:51AM CST
Coronado Biosciences, Inc. (CNDO) was a big mover last session, as its shares rose nearly 9% on the day.
BIIB: 344.49 (+2.16), CNDO: 2.18 (-0.11), ANIP: 54.28 (+2.33), AMAG: 40.04 (-0.79)
Warren Buffett Pick CBI Tumbles On Rating Downgrade
at The Street - Mon Nov 24, 12:00PM CST
Amicus Therapeutics, Inc. (NASDAQ:FOLD), Coronado Biosciences Inc (NASDAQ:CNDO) and Receptos Inc (NASDAQ:RCPT) hit midday posting major gains this Monday. Getting a sluggish start to the week are Fa...
CBI: 39.14 (-1.17), FATE: 3.69 (+0.01), CNDO: 2.18 (-0.11), RCPT: 120.08 (-1.38), FOLD: 8.15 (+0.18)
CB Pharma on deck for IPO
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 10:46AM CST
IPO: 22.83 (-0.07), BIS: 46.11 (+0.99), BIB: 128.83 (-3.16), CNDO: 2.18 (-0.11), IBB: 306.10 (-3.95), DRGS: 52.31 (-1.38), IXJ: 101.03 (-1.47), IRY: 47.43 (-0.71)
Rackspace Bounces, Making Dan Loeb $34 Million In The Process
at The Street - Tue Nov 11, 1:06PM CST
Coronado Biosciences Inc (NASDAQ:CNDO), Rackspace Hosting, Inc. (NYSE:RAX) and AuRico Gold Inc (NYSE:AUQ) are making notable climbs on the stock market this Tuesday. Town Sports International Holding...
RDUS: 26.38 (+1.78), CLUB: 6.22 (+0.01), RAX: 45.39 (-0.86), CNDO: 2.18 (-0.11), AUQ: 3.30 (-0.02)
InsiderInsights.com Daily Round Up 11/10/14: CHK, TWX, SGEN, PBFX
InsiderInsights - at Seeking Alpha - Tue Nov 11, 2:29AM CST
HAS: 56.06 (-0.24), VR: 40.85 (-0.48), SEIC: 39.56 (-0.69), DRNA: 12.88 (+1.19), HA: 23.65 (-0.26), SAM: 279.40 (-0.97), PBFX: 20.00 (-0.76), AMRI: 15.84 (-0.14), GSAT: 2.58 (+0.05), TNET: 30.06 (-0.19), TWX: 82.12 (-1.19), HLT: 25.87 (-0.39), Q: 57.37 (-0.11), SGEN: 32.25 (-1.49), CF: 248.80 (-3.12), OPK: 8.18 (-0.11), CHK: 17.24 (+0.53), CNDO: 2.18 (-0.11), CO: 4.25 (-0.09), CPLA: 69.55 (+1.23)
Coronado Biosciences Raises $3,500,000 Through the Private Placement of Restricted Common Stock
GlobeNewswire - Fri Nov 07, 7:38AM CST
Shares were sold at the closing price on November 6, 2014
CNDO: 2.18 (-0.11)
Coronado Biosciences Reports Financial Results
GlobeNewswire - Thu Nov 06, 6:08AM CST
Coronado Biosciences, Inc. (Nasdaq:CNDO) announced its financial results for the third quarter ended September 30, 2014. Coronado's net cash and restricted cash totaled $71.6 million and $15.4 million respectively at September 30, 2014. The Company posted a quarterly net loss of $4.6 million and $16.7 million, or $0.13 and $0.46 per share for the three and nine months ended September 30, 2014 respectively. These results compare to a net loss of $7.8 million and $27.4 million, or $0.24 and $0.95 per share for the three and nine months ended September 30, 2013 respectively.
CNDO: 2.18 (-0.11)
EC approves ulcerative colitis med
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 10:31AM CDT
SGYP: 2.93 (-0.05), JNJ: 104.43 (-2.29), ABT: 43.69 (-0.77), CNDO: 2.18 (-0.11), PFE: 30.95 (-0.70), SHPG: 213.70 (-0.41), VBLX: 11.15 (+0.15), SLXP: 103.36 (-2.79), RCPT: 120.08 (-1.38), ABBV: 65.27 (-1.76), ATHX: 1.36 (+0.05)
Coronado Biosciences Forms Subsidiary to Acquire and License Dermatology Products for Commercialization
GlobeNewswire - Wed Oct 08, 7:35AM CDT
Coronado Biosciences, Inc. (Nasdaq:CNDO) has formed a wholly owned subsidiary, Journey Medical Corporation (JMC), to acquire and license dermatology products. Under the leadership of Claude Maraoui, CEO, JMC will begin building a portfolio of dermatological assets focused on acne, steroid responsive dermatoses, pigmentation and antifungals for promotion to dermatologists and pediatricians.
CNDO: 2.18 (-0.11)
Kamada Plunges Following Missed Marks In Trial
at The Street - Thu Sep 04, 11:52AM CDT
UTi Worldwide Inc. (NASDAQ:UTIW), Flexion Therapeutics Inc (NASDAQ:FLXN) and PVH Corp (NYSE
VH) are today's top-gaining billionaire stock picks midday. On the losing end are Kamada Ltd (NASDAQ:KM... UTIW: 11.07 (-0.33), FLXN: 18.91 (+1.60), CNDO: 2.18 (-0.11), KMDA: 3.51 (-0.02), CIEN: 18.12 (-0.02), PVH: 127.03 (+1.47)
Coronado Falls on TSO Study Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 10:20AM CDT
Coronado (CNDO) announced disappointing top-line results from a pilot study on TSO.
BIIB: 344.49 (+2.16), MDCO: 25.39 (-0.19), CNDO: 2.18 (-0.11), REGN: 416.44 (-7.91)
Coronado Biosciences Reports Topline Results From Investigator Initiated Pilot Study of TSO in Adults With Autism Spectrum Disorder
GlobeNewswire - Thu Jun 26, 7:50AM CDT
Coronado Biosciences, Inc. (Nasdaq:CNDO) today announced that Dr. Eric Hollander, Clinical Professor Psychiatry and Behavioral Sciences at Albert Einstein College of Medicine of Yeshiva University and Director of the Autism and Obsessive Compulsive Spectrum Program at Montefiore Medical Center and Einstein has completed his pilot study of oral TSO (Trichuris suis ova or CNDO-201) for adults with Autism Spectrum Disorder (ASD).
CNDO: 2.18 (-0.11)
Autism - Pipeline Review, H1 2014 - 20 Companies & 42 Drug Profiles
M2 - Fri Jun 20, 2:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ltzhjv/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Dainippon Sumitomo Pharma Co., Ltd. - Novartis AG - Merz Pharma GmbH & Co. KgaA - Teva Pharmaceutical Industries Limited - Avanir Pharmaceuticals, Inc. - Snowdon Inc. - Curemark, LLC - Coronado Biosciences, Inc. - Omeros Corporation - Intra-Cellular Therapies, Inc. - Cellceutix Corporation - Heptares Therapeutics Ltd. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Naurex, Inc. - Nectid, Inc. - Mnemosyne Pharmaceuticals, Inc. - BioCrea GmbH - Saniona AB Drug Profiles - CM-AT - lurasidone hydrochloride - aripiprazole - cycloserine - fluoxetine - oxytocin - oxytocin - memantine hydrochloride - TSO - pioglitazone hydrochloride - oxytocin - oxytocin - (dextromethorphan hydrobromide quinidine sulfate) - oxytocin - oxytocin - RG-7314 - fluoxetine - fluoxetine - argipressin tannate - NU-211-01 NC-215-01 - Autologous Hematopoietic Stem Cells - glatiramer acetate - ITI-007 - Stem Cell Therapy for Central Nervous System Disorders - KM-391 - Program For Neurological Disorders - STX-110 - CN-2097 - acamprosate calcium - Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome For more information visit http://www.researchandmarkets.com/research/lt...m_pipeline
CNDO: 2.18 (-0.11), TEVA: 55.92 (-0.92), ITCI: 15.79 (-0.47), OMER: 22.81 (+0.12), NVS: 93.52 (-0.82)
Global Autism Clinical Trials Review 2014
M2 - Tue Jun 17, 9:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vhfbw6/autism_global) has announced the addition of the "Autism Global Clinical Trials Review, H1, 2014" report to their offering. Autism Global Clinical Trials Review, H1, 2014 provides data on the Autism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Autism. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Autism. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Autism Speaks, Inc. - Seaside Therapeutics, LLC - Forest Laboratories, Inc. - Johnson & Johnson - Otsuka Holdings Co., Ltd. - F. Hoffmann-La Roche Ltd. - Bristol-Myers Squibb Company - Coronado Biosciences, Inc. - ZonMw - Dainippon Sumitomo Pharma Co., Ltd. - National Institute of Mental Health - Massachusetts General Hospital - Tehran University of Medical Sciences - Eunice Kennedy Shriver National Institute of Child Health and Human Development - Hugo W. Moser Research Institute at Kennedy Krieger, Inc. - Stanford University - The University of Hong Kong - University of California, Los Angeles - Mount Sinai Hospital - University of California, San Francisco For more information visit http://www.researchandmarkets.com/research/vh...ism_global
JNJ: 104.43 (-2.29), CNDO: 2.18 (-0.11), BMY: 58.75 (-0.93), FRX: 99.00 (-0.77)
Arkansas Leading Change in College Student Experience
Marketwire - Tue Feb 25, 6:04AM CST
Today, Achieving the Dream released Continuous Improvement for College Completion: Arkansas Builds a System-Level Strategy for Community College Student Success during a session at DREAM 2014. This report details the coordinated efforts of Arkansas that has significantly improved the progress of student outcomes at two-year colleges across the state.
CNDO: 2.18 (-0.11)
Healthcare Companies Report Interim Data, Clinical Study Results, and Announcements - Research Report on Pfizer, Coronado Biosciences, Spectranetics, Celsion, and Intercept
PR Newswire - Wed Dec 18, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Coronado Biosciences, Inc. (NASDAQ: CNDO), The Spectranetics Corporation (NASDAQ: SPNC), Celsion Corp. (NASDAQ: CLSN), and Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
SPNC: 34.37 (+0.70), CLSN: 2.42 (unch), CNDO: 2.18 (-0.11), AUQ: 3.30 (-0.02), PFE: 30.95 (-0.70), ICPT: 137.69 (-2.48), AUQ.TO: 3.82 (-0.01)
